Winter storm warnings include northeast Twin Cities

MPR News helps you turn down the noise and build shared understanding. Turn up your support for this public resource and keep trusted journalism accessible to all. 

Turn Up Your Support

Martin Shkreli, the former pharmaceutical executive who inspired wrath when he raised the price of a life-saving drug by 5,000 percent, appeared before the House Oversight and Government Reform Committee on Thursday for a hearing on prescription drug prices.


You may remember that Shkreli, the founder and former CEO of Turing Pharmaceuticals, became infamous last year. His company bought the rights to the drug Daraprim, which treats a deadly parasitic infection, and 

raised the price from $13 a pill to $750 a pill

. The company later backed off that increase, but Shkreli defended the decision as simply a good business decision.

Separately, he's been 

 over a hedge fund he managed from 2009 to 2014. In December, he 

.
Shkreli appeared before the House committee on Thursday to discuss drug pricing. The hearing also featured testimony from Dr. Janet Woodcock and Keith Flanagan of the FDA, Howard Schiller of Valeant Pharmaceuticals (which also 

), Nancy Retzlaff of Turing and Mark Merritt of the Pharmaceutical Care Management Association.


In Turing's defense, Retzlaff said that two-thirds of patients receive Daraprim at a steep discount through government programs, and that the company funds an assistance program for uninsured, low-income patients.

Shkreli was much more tight-lipped. His lawyer had advised him to plead the Fifth. And Shkreli followed that advice to the letter.

After Shkreli declined to give an opening statement, here's how the first exchange went:


Shkreli confirmed the pronunciation of his name, but otherwise refused to answer all questions directed his way — even one about his exclusive hip-hop album. (Shkreli bought 

 he still hadn't listened to the album, but 


Shkreli isn't usually so reticent. He has been 

 in his conversations with reporters — and his 

In fact, his new lawyer has said he agreed to represent Shkreli on one condition: The 32-year-old had to stop granting interviews with the press.

A visibly frustrated Rep. Trey Gowdy pointed out that Shkreli could answer a wide range of questions without incriminating himself.

"I intend to follow the advice of my counsel, not yours," the former pharmaceutical executive said with a tight smile.

"Well, Mr. Chairman, I am vexed," Gowdy said, pointing to Shkreli's readiness to talk to the press, but not to Congress.

Rep. Elijah Cummings, for his part, didn't even attempt to question Shkreli, and instead pleaded with him — arguing that Shkreli could use his position, and his influence over his former company, as a force for good. Cummings said Shkreli could use his influence to advocate for patients' rights and could "make a difference in so many people's lives."

"I know you're smiling," Cummings said, "But I'm very serious, sir. The way I see it, you can go down in history as the poster boy for greedy drug company executives, or you could change the system.

An earlier version of this post misspelled the last name of Turing Pharmaceuticals executive Nancy Retzlaff as Retzclaff.

Politics and Government News

The much-reviled former pharmaceutical executive remained tight-lipped, pleading the Fifth Amendment on his lawyer's advice. He simply smiled in response to harsh criticism from House representatives.

No comment from grinning Martin Shkreli at House hearing on drug prices

Go Deeper.

Like this?